ONCOLOGY Vol 27 No 8 | Oncology

Introducing a New Resource for Readers of ONCOLOGY: The American College of Radiology Appropriateness Criteria

August 15, 2013

The ACR Appropriateness Criteria®, and their mission to improve the knowledge of practicing oncologists and the level of care our patients receive, is wholly consistent with the goals of ONCOLOGY. We are hopeful that our readership will find the ACR Appropriateness Criteria® a valuable resource in their day-to-day practice. I personally look forward to future guidelines in this series.

Ductal Carcinoma In Situ of the Breast: ‘Making the Punishment Fit the Crime’

August 15, 2013

To make the punishment fit the crime, you would want the decision of whether or not to use adjuvants to be informed by the degree of risk that the DCIS would recur. What factors can predict for an increased risk of recurrence, or more importantly, the risk of an invasive breast cancer occurring?

Rare Myelomas: Sometimes When You Hear Hooves, It’s a Zebra...

August 15, 2013

The use of newer methods of disease assessment that focus on minimal residual disease may facilitate the long-term evaluation of IgD and IgE myeloma patients, even if the rare Ig subtype is not identified at diagnosis.

Nonseminomatous Germ Cell Tumor of Testis and Interrupted Treatment

August 15, 2013

A 22-year-old man presented to the emergency department with a 5-cm painful testicular mass that had increased in size over the previous month. Tumor markers were drawn and an inguinal orchiectomy was performed.

Unusual Myelomas: A Review of IgD and IgE Variants

August 15, 2013

Although survival of patients with IgD or IgE multiple myeloma is shorter in comparison to those with IgG or IgA multiple myeloma, the outcome for patients with IgD and IgE subtypes is improving with the use of novel agents and autologous transplantation.

ACR Appropriateness Criteria® Localized Nodal Indolent Lymphoma

August 15, 2013

The present guidelines review epidemiology, pathology, presentation, workup, staging, prognostic factors, and treatment options for patients with localized nodal indolent lymphoma, with an emphasis on radiation guidelines, including radiation dose, field design, and radiation techniques.

Use of Molecular Biomarkers to Inform Adjuvant Therapy for Colon Cancer

August 15, 2013

In this review, we will discuss adjuvant chemotherapy in non-metastatic colon cancer, the existing prognostic and predictive molecular biomarkers in the field, and how to integrate these molecular biomarkers into the decision about whether to administer adjuvant therapy.